NASDAQ$BCPC

Balchem Corporation · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Balchem delivered solid second quarter financials with record earnings from operations and adjusted EBITDA.

Balchem Corporation reported a 1.2% increase in net sales to $234.1 million for the second quarter of 2024. GAAP net earnings increased by 6.5% to $32.1 million, with earnings per share at $0.98. Adjusted EBITDA reached a record $62.3 million, a 5.0% increase from the prior year quarter. The Human Nutrition and Health and Specialty Products segments showed strong sales and earnings growth.

  • Net sales increased by 1.2% to $234.1 million compared to the prior year quarter.
  • Adjusted EBITDA reached a record $62.3 million, a 5.0% increase from the prior year quarter.
  • GAAP net earnings increased by 6.5% to $32.1 million, with earnings per share at $0.98.
  • Human Nutrition and Health and Specialty Products segments delivered strong sales and earnings growth.

Headline financials

Total Revenue

$234M

Previous: $231M+1.2%
EPS

$0.98

Previous: $0.94+4.3%
Capital Expenditures

-$6.88M

Previous: -$17.5M+60.7%
Free Cash Flow

$32.1M

Previous: $12.6M+154.6%
Net Income

$32.1M

Previous: $30.1M+6.5%
Operating Income

$45.8M

Previous: $42.8M+6.9%
Gross Profit

$83M

Previous: $77.3M+7.3%
Cash & Equivalents

$63.7M

Previous: $66.9M-4.7%
Total Assets

$1.57B

Previous: $1.62B-2.7%
R&D Expense

$3.85M

No prior period
Stock-Based Comp

$3.89M

Previous: $3.75M+3.7%

Revenue & EPS history

Balchem · Revenue · Quarterly

$234M

Q2 2024+1.2%vs Q2 2023
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Balchem · $228M total across 3 segments · Q3 2023

  • Human Nutrition & Health
    $144M+1.3%
  • Animal Nutrition & Health
    $53.9M-17.8%
  • Specialty Products
    $30M+1.2%

Forward guidance

We are well positioned in the markets we serve and remain confident in the long-term growth outlook for our company as we continue to focus on progressing our strategic growth initiatives in 2024 and beyond.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.0%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.9%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+25.0%

Q1 2014

Best reaction

-16.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.8%-7.0%-9.7%
Q4 2025-2.3%+2.6%-7.4%
Q3 2025+4.1%+3.9%+1.3%
Q1 2025-2.6%-1.5%+4.8%
Q4 2024+1.5%+7.0%-0.1%
Q3 2024+2.8%+1.6%+9.8%
Q2 2024+3.9%+1.5%-1.2%
Q1 2024-1.8%-3.0%-8.8%
Q4 2023+7.4%+5.0%+6.8%
Q3 2023-5.0%-4.1%+1.1%
Q2 2023+4.8%+5.0%+7.1%
Q1 2023+1.7%+0.5%+5.2%
Q4 2022-2.0%-0.2%-7.7%
Q3 2022-0.6%-0.5%+5.4%
Q2 2022-5.2%-6.6%+2.3%
Q1 2022+1.6%-0.9%-10.5%
Q4 2021+1.0%-0.7%+1.2%
Q3 2021-0.8%+2.3%+7.9%
Q2 2021-0.8%-2.5%+2.7%
Q1 2021-0.2%-0.1%+0.5%
Q4 2020+5.4%+6.4%+10.7%
Q3 2020-1.7%-0.5%+3.3%
Q2 2020+4.6%+4.7%+0.3%
Q1 2020-5.4%-3.9%-9.3%
Q4 2019-10.7%-13.3%-15.9%
Q3 2019+2.9%+1.2%-0.8%
Q2 2019-16.3%-15.9%-13.5%
Q1 2019+1.1%+4.0%+9.4%
Q4 2018+8.0%+12.4%+10.7%
Q3 2018-4.9%-4.9%-13.7%
Q2 2018+1.1%+1.3%+10.1%
Q1 2018-1.3%+2.2%+7.9%
Q4 2017+2.3%+5.9%+8.6%
Q3 2017+1.0%-0.7%+1.3%
Q2 2017-2.6%-3.9%-1.8%
Q1 2017-3.3%-5.3%-1.8%
Q4 2016+5.2%+2.2%-2.5%
Q3 2016-4.5%+0.8%+12.3%
Q2 2016+1.3%+2.0%+8.7%
Q1 2016+0.3%
Q4 2015-0.4%
Q3 2015-2.0%
Q2 2015+5.2%
Q1 2015-0.5%
Q4 2014-3.4%
Q3 2014+6.7%
Q2 2014+2.5%
Q1 2014+25.0%
Q4 2013+0.4%
Q3 2013-4.9%
Q2 2013+1.3%
Q1 2013-2.3%
Q4 2012+0.8%
Q3 2012-10.5%
Q2 2012+5.9%
Q1 2011+2.1%
Q4 2011+2.1%
Q1 2012+2.4%
Q1 2010-4.1%
Q4 2009-4.1%
Q3 2010-3.2%
Q3 2011-3.2%
Q2 2011+1.0%
Q4 2010+1.0%
Q2 2010+1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro